Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07642973

A Study to Evaluate the Safety and Clinical Performance of a Dexpanthenol Medicated Hydrogel Patch in the Treatment of Standardized Superficial Abrasions

Clinical evaluation of a Dexpanthenol-medicated wound plaster on standardized superficial skin abrasions

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Age range

18 year–64 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

la U.O.C. Anestesia Rianimazione degli Ospedali Riuniti Padova Sud

Monselice, PD, 35043, Italy

Location contact

Alessandro Guzzo, MD

CONTACT

[email protected]

+39 0429714111

Alessandro Guzzo, MD

PRINCIPAL_INVESTIGATOR

About this study

By utilizing a standardized abrasion model (based on the Wigger-Alberti methodology), the study aims to quantify the superior clinical performance of the Plaster compared to a standard plaster (conventional dry) and dry healing (no plaster). This evidence is crucial to demonstrate that the presence of Dexpanthenol provides a significant clinical benefit in terms of healing speed and aesthetic quality of the repaired tissue.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy male or female volunteers aged 18 to 64 years (inclusive).
  • Informed consent form signed voluntarily before any study-related procedure.
  • Subjects willing and able to comply with all study protocol requirements, including scheduled visits and home-wear restrictions.
  • Intact, healthy skin on both volar forearms (free of tattoos, scars, sunburns, or active skin lesions in the designated test areas).
  • Agree to take precautions to prevent pregnancy (applicable only to non-menopausal women), including abstinence, intrauterine devices (IUDs), progestogen implants, combined estrogenic-progestogen contraceptives, the use of condoms;

Exclusion criteria

  • Known hypersensitivity or allergy to Dexpanthenol, hydrogel components, acrylic adhesives, or any component of the investigational devices.
  • History of keloid formation, hypertrophic scarring, or abnormal wound healing.
  • Active dermatological conditions (e.g., psoriasis, eczema, atopic dermatitis, active infections) on the upper extremities.
  • History of diabetes mellitus, peripheral vascular disease, or arterial/venous microangiopathy.
  • Systemic treatment with corticosteroids, immunosuppressive drugs, Anticoagulants, antiplatelet agents or cytostatic agents within 4 weeks prior to Baseline, or anticipated need during the study.
  • Topical treatment (steroids, retinoids, antibiotics, or moisturizers) applied to the volar forearms within 2 weeks prior to Baseline.
  • Active heavy smokers (more than 10 cigarettes per day) or users of nicotine-replacement therapies (nicotine alters cutaneous microcirculation and significantly impairs wound healing kinetics)
  • Pregnant or lactating women, or women of childbearing potential not using highly effective contraception (see inclusion criteria).
  • Not willing and able to comply with all study protocol requirements

Treatment and study plan

hydrogel plaster with dexpanthenol

Device

On the wound will be applied daily an hydrogel plaster with Dexpanthenol

Standard plaster

Device

On the wound will be daily applicated a standard plaster on the market

Primary outcomes

  1. Re-epithelialization Rate

    Time frame: day 5 day 7 day 15

    Measured as the percentage of wound closure compared to baseline (T0) with standardized photography

Secondary outcomes

  1. Kinetics of Wound Closure

    Time frame: Day 5 day 7

    Time to 50% re-epithelialization

  2. Subject-Reported Pain

    Time frame: day 5 day 7

    Pain during wear and upon plaster removal assessed via a 100-mm Visual Analogue Scale (VAS)

  3. Scar Quality Assessment

    Time frame: day 5 day 7 day 15

    using the Vancouver Scar Scale (VSS) (scoring vascularity, pigmentation, pliability, and height)

  4. general usability

    Time frame: Day 1, day 5, day 7

    Assessment of the plaster adherence to the perilesional skin over the treatment period using a 5-Point Adhesion Score 0 (100%) to 4 (0% fallen)

Other outcomes

  1. Number of AE

    Time frame: from day 1 to day 15 (all the study duration)

    Safety outcome

Study contacts

Contact information is provided by the study sponsor or research team.

Adolfo Gasparetto, MD

CONTACT

[email protected]

+39 3356641965

Alessandro Guzzo, MD

CONTACT

[email protected]

+39 0429715610

Sponsors and collaborators

Lead sponsor

Wooshin Labottach Co., Ltd.

Industry

Collaborators

  • Nextrasearch S.r.l.s.

Registry information

Official study title

A Randomized, Single-Blind, Intra-Individual Controlled Study to Evaluate the Safety and Clinical Performance of a Dexpanthenol Medicated Hydrogel Patch in the Treatment of Standardized Superficial Abrasions

Acronym: Dexpanthenol

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Jun 11, 2026
Registry last updated
Jun 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.